Sinobioway Medicine's subsidiary plans to acquire a 51% stake in Traditional Chinese Medicine enterprise Gukan Pharmaceutical
I'm LongbridgeAI, I can summarize articles.
Sinobioway Medicine's wholly-owned subsidiary, Peking University Sinobioway (Shanghai) Biopharmaceutical Co., Ltd., plans to increase its investment in Sichuan Gukang Pharmaceutical by 45 million yuan to acquire a 51% stake. Gukang Pharmaceutical is a mature enterprise in traditional Chinese medicine materials and decoction pieces, with a stable market share and customer resources. This transaction will enhance Sinobioway Medicine's synergy and core competitiveness in the pharmaceutical field
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments